Interview With Christi Myers

What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.

MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.

MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #JNJ #MNMD

In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).

We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

Time Stamps
0:00​ – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates

So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

What’s up psychedelic investors! Today we’re finally going to cover the long anticipated NUMIStock. Numinus Wellness is a psychedelic Medicines company using a variety of compounds like psilocybin, MDMA and ketamine to treat for addiction, PTSD, depression and more. You can find the NUMI Stock on the TSX Venture exchange under the ticker symbol NUMI. NUMI stock is currently trading around 1$ Canadian, with a market cap of around $200 million. If you don’t want to purchase NUMI individually, Numinus can also be partially owned through an ETF like Horizons Psychedelic Stock Index or the upcoming Advisor Shares Plant Medicine ETF.

In this video we will cover the problems Numinus is trying to solve, their flagship programs, their financials, and finally the risks for the company. Numinus Wellness is one of the first psychedelic stocks we covered on this channel and the company has advanced quite nicely in the past few months, making it an interesting pick for the shroom boom!

Time Stamps
0:00 – Intro
1:20 – What Problem is Numinus trying to solve?
3:22 – NuMi Ketamine Treatments for Depression
4:50 – MDMA to treat PTSD
6:24 – Numinus Wellness Treating Addiction with Psilocybin
7:48 – Special Access Trials for MDMA and Psilocybin
9:02 – Psilocybin Extraction from Magic Mushrooms
9:39 – Financials and Cash on Hand
11:29 – Risks

https://www.newswire.ca/news-releases/numinus-wellness-closes-q1-2021-with-strong-cash-position-and-industry-firsts-867457159.html?fbclid=IwAR3gKruRdmOGIBZeRmS_xU-R_0J4WehW5TodKLx7SWK19DdpEeoZhM8O-2c#:~:text=Achievedcashbalanceof4915209,(1928737)forQ12021

So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

If you want to collaborate, send us an email!
thepsychedelicinvestor@gmail.com

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#NuminusWellness #NUMIStock #MindMed

Who’s next in line to Uplist to the Nasdaq? Numinus? Cybin? FieldTrip? ALL of them??
Today, I’ll be covering an article by Jeff Neilson published on The Psychedelic Stock Watch. In this article, Jeff outlines several stocks as contenders for an uplisting.

* Cybin Inc (CAN:CYBN / US:CLXPF) : Cybin is also one of the more successful companies in raising capital, having raised ~CAD$88.8 million (US$70 million) since going public last November and as we have been repeating on this channel, capital is a very important factor for the successful continuation and advancement of clinical trials.

*Field Trip Health (CAN:FTRP / US:FTRPF) : Field Trip Health shares some similarities with Cybin as an uplisting prospect. It has raised even more capital than Cybin, in excess of US$100 million, including its recent CAD$95 million bought deal financing (US$76 million) and Field Trip has also a price target of CAD$8.50 price target from Stifel GMP to its February 2021 high of CAD$8.25.

*Numinus Wellness (CAN:NUMI / US:LKYSF) : Numinus Wellness actually has a stronger following among retail investors than either Cybin or Field Trip. It was second only to MindMed as the volume leader among psychedelic stocks in the 2020 rally. It was also the second-best performer among all of the leading stocks in that rally, generating a 10X return at its 2020 peak.

However, these are not the only psychedelic stocks to peak Jeff Neilson’s eye.
He also mentions:

Mind Cure Health (CAN:MCUR / US:MCURF)
Mydecine Innovations Group (CAN:MYCO / US:MYCOF)
Bright Minds Biosciences (CAN:DRUG / US:BMBIF)
Small Pharma Inc( it hasn’t even started public trading YET)

Timestamps:
0:00 – Intro
1:55 – Cybin ( CYBN / CXPF )
6:13 – Field Trip Health ( FTRP / FTRPF )
9:05 – Numinus Wellness ( NUMI / LKYSF )
11:35 – Mindcure Health
12:08 – Mydecine ( MYCO /MYCOF )
12:34 – Bright Minds Biosciences ( DRUG / BMBIF )
13:10 – Small Pharma Inc.

Link to the article in question: https://psychedelicstockwatch.com/psychedelic-stock-news/the-next-psychedelic-stock-to-uplist-on-the-nasdaq?fbclid=IwAR3CgezfqtNHk0U3_YX5LYHDU2Y34jEFSTdNVGVchsKgR4CdEj58Q-lYcwk
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Canacord: https://thetradingpriest.com/wp-content/uploads/2021/04/ResearchReport-1.pdf
Link to Numinus (NUMI): https://numinus.ca/
Link to Field Trip ( FTRP / FTRPF) : https://www.fieldtriphealth.com/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Cybin #Numi